4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference
4D Molecular Therapeutics (Nasdaq: FDMT) announced its participation in the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 2:00 p.m. PT. The presentation will be accessible via a live audio webcast on the company’s website, with a replay available for two weeks post-event.
The company focuses on targeted gene therapy using its Therapeutic Vector Evolution platform. Currently, 4DMT is conducting three clinical trials: 4D-125 for XLRP, 4D-110 for choroideremia, and 4D-310 for Fabry disease.
- None.
- None.
EMERYVILLE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will present at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13 at 2:00 p.m. PT.
A live audio webcast of the presentation will be available by visiting the “Investors & Media” section of the 4DMT website at www.4dmoleculartherapeutics.com. A replay of the webcast will be available for at least two weeks following the live event.
About 4DMT
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients.
4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
Contacts:
Media:
Theresa Janke
tjanke@4dmt.com
Investors:
Mike Zanoni
Endurance Advisors
mzanoni@4dmt.com
FAQ
When is 4D Molecular Therapeutics presenting at the BofA Securities Conference?
How can I watch the 4D Molecular Therapeutics presentation?
What clinical trials is 4D Molecular Therapeutics currently conducting?
What is the focus of 4D Molecular Therapeutics?
